Physician profile
Samar Sheriff
NPI 1649730276
$2,575.26
in general payments reported to CMS, 2019-2025
20 companies · $872 in 2025
The $872 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $86.25 · 2022: $75.46 · 2023: $337 · 2024: $1,205 · 2025: $872.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,305 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,305.11 |
| Education | $108.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $706.55 | 2021-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $374.60 | 2023-2025 | Tremfya, Stelara, Simponi Aria |
| Lilly USA, LLC | $272.38 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Novartis Pharmaceuticals Corporation | $177.41 | 2024-2025 | |
| Amgen INC. | $176.10 | 2023-2024 | Otezla |
| Regeneron Healthcare Solutions, INC. | $169.93 | 2021-2025 | Dupixent |
| Ucb, INC. | $93.47 | 2024-2025 | Bimzelx |
| Galderma Laboratories, L.P. | $80.07 | 2024-2025 | Nemluvio, Aklief |
| Incyte Corporation | $75.19 | 2023-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $66.37 | 2024-2025 | Sotyktu |
| Almirall LLC | $52.38 | 2025 | Klisyri |
| Arcutis Biotherapeutics, INC. | $51.83 | 2023-2024 | Zoryve |
| Dermavant Sciences, INC. | $50.31 | 2024 | Vtama |
| Pfizer INC. | $49.93 | 2024-2025 | |
| Organon LLC | $46.64 | 2025 | Vtama |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $42.94 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.58 | 2023 | Spevigo |
| Genentech USA, INC. | $23.99 | 2022 | |
| Leo Pharma INC. | $18.84 | 2023 | Adbry |
| Sun Pharmaceutical Industries INC. | $18.75 | 2023 | Ilumya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samar Sheriff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.